Cardiovascular outcomes of patients treated for non-Hodgkin lymphoma with first-line doxorubicin-based chemotherapy-Reference-Cited by-同舟云学术

Cardiovascular outcomes of patients treated for non-Hodgkin lymphoma with first-line doxorubicin-based chemotherapy

Published:2022-09-18 Issue:14 Volume:63 Page:3340-3350
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Zduniak Alexandra¹,Lévêque Emilie²,Perdrix Anne³⁴,Etancelin Pascaline¹³⁵,Ménard Anne-Lise¹,Lenain Pascal¹,Contentin Nathalie¹,Pépin Louis-Ferdinand²,Leprêtre Stéphane¹,Lemasle Emilie¹,Lanic Hélène¹,Stamatoullas-Bastard Aspasia¹,Kammoun-Quique Leila⁶,Tilly Hervé¹⁵,Bauer Fabrice⁷,Jardin Fabrice¹⁵,Camus Vincent¹⁵

Affiliation:

1. Department of Hematology, Centre Henri Becquerel, Rouen, France

2. Department of Statistics and Clinical Research Unit, Centre Henri Becquerel, Rouen, France

3. Department of Biopathology, Rouen, France

4. IRON Group, INSERM U1245, UNIROUEN, Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, Normandie Université, Rouen, France

5. INSERM U1245, Université de Rouen, IRIB, Rouen, France

6. Department of Hematology-Oncology, Centre Hospitalier d’Evreux, Evreux, France

7. Advanced Heart Failure, Department of Thoracic and cardiovascular Surgery, Charles Nicolle University Hospital, Rouen, France

Funder

iQone Healthcare

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2123222

Reference31 articles.